Adrenoleukodystrophy Treatment Market, Global Outlook and Forecast 2022-2028
Adrenoleukodystrophy refers to a rare genetic condition that causes the buildup of long chain fatty acids (VLCFAs) in the brain. ALD is led by a mutation in the ABCD1 gene on the X chromosome. The three types of adrenoleukodystrophy including Adrenomyelopathy, Childhood cerebral ALD and Addison’s disease. Childhood cerebral ALD is known to progress rapidly in children between the ages of 3 and 10.
This report contains market size and forecasts of Adrenoleukodystrophy Treatment in Global, including the following market information:
Global Adrenoleukodystrophy Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Adrenoleukodystrophy Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Oral Drugs Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Adrenoleukodystrophy Treatment include bluebird bio, Orpheris, MedDay Pharmaceuticals, MINORYX THERAPEUTICS SL, Pfizer, Amgen, AstraZeneca, Abbott and agtc, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Adrenoleukodystrophy Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Adrenoleukodystrophy Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Adrenoleukodystrophy Treatment Market Segment Percentages, by Type, 2021 (%)
Global Adrenoleukodystrophy Treatment Market Segment Percentages, by Application, 2021 (%)
Global Adrenoleukodystrophy Treatment Market Segment Percentages, By Region and Country, 2021 (%)
The report also provides analysis of leading market participants including:
Key companies Adrenoleukodystrophy Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Adrenoleukodystrophy Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
This report contains market size and forecasts of Adrenoleukodystrophy Treatment in Global, including the following market information:
Global Adrenoleukodystrophy Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Adrenoleukodystrophy Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Oral Drugs Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Adrenoleukodystrophy Treatment include bluebird bio, Orpheris, MedDay Pharmaceuticals, MINORYX THERAPEUTICS SL, Pfizer, Amgen, AstraZeneca, Abbott and agtc, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Adrenoleukodystrophy Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Adrenoleukodystrophy Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Adrenoleukodystrophy Treatment Market Segment Percentages, by Type, 2021 (%)
- Oral Drugs
- Parenteral Drugs
Global Adrenoleukodystrophy Treatment Market Segment Percentages, by Application, 2021 (%)
- Hospital
- Clinic
- Home Care
Global Adrenoleukodystrophy Treatment Market Segment Percentages, By Region and Country, 2021 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
The report also provides analysis of leading market participants including:
Key companies Adrenoleukodystrophy Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Adrenoleukodystrophy Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
- bluebird bio
- Orpheris
- MedDay Pharmaceuticals
- MINORYX THERAPEUTICS SL
- Pfizer
- Amgen
- AstraZeneca
- Abbott
- agtc
- ReceptoPharm
- The Myelin Project
- SOM Biotech
- Viking Therapeutics
- Nutra Pharma Corporation
- Genetix Biotech
- Magenta Therapeutics
- NeuroVia
- Novartis
- CELGENE CORPORATION
- Jazz Pharmaceuticals
- Sanofi
1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS
1.1 Adrenoleukodystrophy Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Adrenoleukodystrophy Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 GLOBAL ADRENOLEUKODYSTROPHY TREATMENT OVERALL MARKET SIZE
2.1 Global Adrenoleukodystrophy Treatment Market Size: 2021 VS 2028
2.2 Global Adrenoleukodystrophy Treatment Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 COMPANY LANDSCAPE
3.1 Top Adrenoleukodystrophy Treatment Players in Global Market
3.2 Top Global Adrenoleukodystrophy Treatment Companies Ranked by Revenue
3.3 Global Adrenoleukodystrophy Treatment Revenue by Companies
3.4 Top 3 and Top 5 Adrenoleukodystrophy Treatment Companies in Global Market, by Revenue in 2021
3.5 Global Companies Adrenoleukodystrophy Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Adrenoleukodystrophy Treatment Players in Global Market
3.6.1 List of Global Tier 1 Adrenoleukodystrophy Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 Adrenoleukodystrophy Treatment Companies
4 MARKET SIGHTS BY PRODUCT
4.1 Overview
4.1.1 by Type - Global Adrenoleukodystrophy Treatment Market Size Markets, 2021 & 2028
4.1.2 Oral Drugs
4.1.3 Parenteral Drugs
4.2 By Type - Global Adrenoleukodystrophy Treatment Revenue & Forecasts
4.2.1 By Type - Global Adrenoleukodystrophy Treatment Revenue, 2017-2022
4.2.2 By Type - Global Adrenoleukodystrophy Treatment Revenue, 2023-2028
4.2.3 By Type - Global Adrenoleukodystrophy Treatment Revenue Market Share, 2017-2028
5 SIGHTS BY APPLICATION
5.1 Overview
5.1.1 By Application - Global Adrenoleukodystrophy Treatment Market Size, 2021 & 2028
5.1.2 Hospital
5.1.3 Clinic
5.1.4 Home Care
5.2 By Application - Global Adrenoleukodystrophy Treatment Revenue & Forecasts
5.2.1 By Application - Global Adrenoleukodystrophy Treatment Revenue, 2017-2022
5.2.2 By Application - Global Adrenoleukodystrophy Treatment Revenue, 2023-2028
5.2.3 By Application - Global Adrenoleukodystrophy Treatment Revenue Market Share, 2017-2028
6 SIGHTS BY REGION
6.1 By Region - Global Adrenoleukodystrophy Treatment Market Size, 2021 & 2028
6.2 By Region - Global Adrenoleukodystrophy Treatment Revenue & Forecasts
6.2.1 By Region - Global Adrenoleukodystrophy Treatment Revenue, 2017-2022
6.2.2 By Region - Global Adrenoleukodystrophy Treatment Revenue, 2023-2028
6.2.3 By Region - Global Adrenoleukodystrophy Treatment Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Adrenoleukodystrophy Treatment Revenue, 2017-2028
6.3.2 US Adrenoleukodystrophy Treatment Market Size, 2017-2028
6.3.3 Canada Adrenoleukodystrophy Treatment Market Size, 2017-2028
6.3.4 Mexico Adrenoleukodystrophy Treatment Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Adrenoleukodystrophy Treatment Revenue, 2017-2028
6.4.2 Germany Adrenoleukodystrophy Treatment Market Size, 2017-2028
6.4.3 France Adrenoleukodystrophy Treatment Market Size, 2017-2028
6.4.4 U.K. Adrenoleukodystrophy Treatment Market Size, 2017-2028
6.4.5 Italy Adrenoleukodystrophy Treatment Market Size, 2017-2028
6.4.6 Russia Adrenoleukodystrophy Treatment Market Size, 2017-2028
6.4.7 Nordic Countries Adrenoleukodystrophy Treatment Market Size, 2017-2028
6.4.8 Benelux Adrenoleukodystrophy Treatment Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Adrenoleukodystrophy Treatment Revenue, 2017-2028
6.5.2 China Adrenoleukodystrophy Treatment Market Size, 2017-2028
6.5.3 Japan Adrenoleukodystrophy Treatment Market Size, 2017-2028
6.5.4 South Korea Adrenoleukodystrophy Treatment Market Size, 2017-2028
6.5.5 Southeast Asia Adrenoleukodystrophy Treatment Market Size, 2017-2028
6.5.6 India Adrenoleukodystrophy Treatment Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Adrenoleukodystrophy Treatment Revenue, 2017-2028
6.6.2 Brazil Adrenoleukodystrophy Treatment Market Size, 2017-2028
6.6.3 Argentina Adrenoleukodystrophy Treatment Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Adrenoleukodystrophy Treatment Revenue, 2017-2028
6.7.2 Turkey Adrenoleukodystrophy Treatment Market Size, 2017-2028
6.7.3 Israel Adrenoleukodystrophy Treatment Market Size, 2017-2028
6.7.4 Saudi Arabia Adrenoleukodystrophy Treatment Market Size, 2017-2028
6.7.5 UAE Adrenoleukodystrophy Treatment Market Size, 2017-2028
7 PLAYERS PROFILES
7.1 bluebird bio
7.1.1 bluebird bio Corporate Summary
7.1.2 bluebird bio Business Overview
7.1.3 bluebird bio Adrenoleukodystrophy Treatment Major Product Offerings
7.1.4 bluebird bio Adrenoleukodystrophy Treatment Revenue in Global Market (2017-2022)
7.1.5 bluebird bio Key News
7.2 Orpheris
7.2.1 Orpheris Corporate Summary
7.2.2 Orpheris Business Overview
7.2.3 Orpheris Adrenoleukodystrophy Treatment Major Product Offerings
7.2.4 Orpheris Adrenoleukodystrophy Treatment Revenue in Global Market (2017-2022)
7.2.5 Orpheris Key News
7.3 MedDay Pharmaceuticals
7.3.1 MedDay Pharmaceuticals Corporate Summary
7.3.2 MedDay Pharmaceuticals Business Overview
7.3.3 MedDay Pharmaceuticals Adrenoleukodystrophy Treatment Major Product Offerings
7.3.4 MedDay Pharmaceuticals Adrenoleukodystrophy Treatment Revenue in Global Market (2017-2022)
7.3.5 MedDay Pharmaceuticals Key News
7.4 MINORYX THERAPEUTICS SL
7.4.1 MINORYX THERAPEUTICS SL Corporate Summary
7.4.2 MINORYX THERAPEUTICS SL Business Overview
7.4.3 MINORYX THERAPEUTICS SL Adrenoleukodystrophy Treatment Major Product Offerings
7.4.4 MINORYX THERAPEUTICS SL Adrenoleukodystrophy Treatment Revenue in Global Market (2017-2022)
7.4.5 MINORYX THERAPEUTICS SL Key News
7.5 Pfizer
7.5.1 Pfizer Corporate Summary
7.5.2 Pfizer Business Overview
7.5.3 Pfizer Adrenoleukodystrophy Treatment Major Product Offerings
7.5.4 Pfizer Adrenoleukodystrophy Treatment Revenue in Global Market (2017-2022)
7.5.5 Pfizer Key News
7.6 Amgen
7.6.1 Amgen Corporate Summary
7.6.2 Amgen Business Overview
7.6.3 Amgen Adrenoleukodystrophy Treatment Major Product Offerings
7.6.4 Amgen Adrenoleukodystrophy Treatment Revenue in Global Market (2017-2022)
7.6.5 Amgen Key News
7.7 AstraZeneca
7.7.1 AstraZeneca Corporate Summary
7.7.2 AstraZeneca Business Overview
7.7.3 AstraZeneca Adrenoleukodystrophy Treatment Major Product Offerings
7.7.4 AstraZeneca Adrenoleukodystrophy Treatment Revenue in Global Market (2017-2022)
7.7.5 AstraZeneca Key News
7.8 Abbott
7.8.1 Abbott Corporate Summary
7.8.2 Abbott Business Overview
7.8.3 Abbott Adrenoleukodystrophy Treatment Major Product Offerings
7.8.4 Abbott Adrenoleukodystrophy Treatment Revenue in Global Market (2017-2022)
7.8.5 Abbott Key News
7.9 agtc
7.9.1 agtc Corporate Summary
7.9.2 agtc Business Overview
7.9.3 agtc Adrenoleukodystrophy Treatment Major Product Offerings
7.9.4 agtc Adrenoleukodystrophy Treatment Revenue in Global Market (2017-2022)
7.9.5 agtc Key News
7.10 ReceptoPharm
7.10.1 ReceptoPharm Corporate Summary
7.10.2 ReceptoPharm Business Overview
7.10.3 ReceptoPharm Adrenoleukodystrophy Treatment Major Product Offerings
7.10.4 ReceptoPharm Adrenoleukodystrophy Treatment Revenue in Global Market (2017-2022)
7.10.5 ReceptoPharm Key News
7.11 The Myelin Project
7.11.1 The Myelin Project Corporate Summary
7.11.2 The Myelin Project Business Overview
7.11.3 The Myelin Project Adrenoleukodystrophy Treatment Major Product Offerings
7.11.4 The Myelin Project Adrenoleukodystrophy Treatment Revenue in Global Market (2017-2022)
7.11.5 The Myelin Project Key News
7.12 SOM Biotech
7.12.1 SOM Biotech Corporate Summary
7.12.2 SOM Biotech Business Overview
7.12.3 SOM Biotech Adrenoleukodystrophy Treatment Major Product Offerings
7.12.4 SOM Biotech Adrenoleukodystrophy Treatment Revenue in Global Market (2017-2022)
7.12.5 SOM Biotech Key News
7.13 Viking Therapeutics
7.13.1 Viking Therapeutics Corporate Summary
7.13.2 Viking Therapeutics Business Overview
7.13.3 Viking Therapeutics Adrenoleukodystrophy Treatment Major Product Offerings
7.13.4 Viking Therapeutics Adrenoleukodystrophy Treatment Revenue in Global Market (2017-2022)
7.13.5 Viking Therapeutics Key News
7.14 Nutra Pharma Corporation
7.14.1 Nutra Pharma Corporation Corporate Summary
7.14.2 Nutra Pharma Corporation Business Overview
7.14.3 Nutra Pharma Corporation Adrenoleukodystrophy Treatment Major Product Offerings
7.14.4 Nutra Pharma Corporation Adrenoleukodystrophy Treatment Revenue in Global Market (2017-2022)
7.14.5 Nutra Pharma Corporation Key News
7.15 Genetix Biotech
7.15.1 Genetix Biotech Corporate Summary
7.15.2 Genetix Biotech Business Overview
7.15.3 Genetix Biotech Adrenoleukodystrophy Treatment Major Product Offerings
7.15.4 Genetix Biotech Adrenoleukodystrophy Treatment Revenue in Global Market (2017-2022)
7.15.5 Genetix Biotech Key News
7.16 Magenta Therapeutics
7.16.1 Magenta Therapeutics Corporate Summary
7.16.2 Magenta Therapeutics Business Overview
7.16.3 Magenta Therapeutics Adrenoleukodystrophy Treatment Major Product Offerings
7.16.4 Magenta Therapeutics Adrenoleukodystrophy Treatment Revenue in Global Market (2017-2022)
7.16.5 Magenta Therapeutics Key News
7.17 NeuroVia
7.17.1 NeuroVia Corporate Summary
7.17.2 NeuroVia Business Overview
7.17.3 NeuroVia Adrenoleukodystrophy Treatment Major Product Offerings
7.17.4 NeuroVia Adrenoleukodystrophy Treatment Revenue in Global Market (2017-2022)
7.17.5 NeuroVia Key News
7.18 Novartis
7.18.1 Novartis Corporate Summary
7.18.2 Novartis Business Overview
7.18.3 Novartis Adrenoleukodystrophy Treatment Major Product Offerings
7.18.4 Novartis Adrenoleukodystrophy Treatment Revenue in Global Market (2017-2022)
7.18.5 Novartis Key News
7.19 CELGENE CORPORATION
7.19.1 CELGENE CORPORATION Corporate Summary
7.19.2 CELGENE CORPORATION Business Overview
7.19.3 CELGENE CORPORATION Adrenoleukodystrophy Treatment Major Product Offerings
7.19.4 CELGENE CORPORATION Adrenoleukodystrophy Treatment Revenue in Global Market (2017-2022)
7.19.5 CELGENE CORPORATION Key News
7.20 Jazz Pharmaceuticals
7.20.1 Jazz Pharmaceuticals Corporate Summary
7.20.2 Jazz Pharmaceuticals Business Overview
7.20.3 Jazz Pharmaceuticals Adrenoleukodystrophy Treatment Major Product Offerings
7.20.4 Jazz Pharmaceuticals Adrenoleukodystrophy Treatment Revenue in Global Market (2017-2022)
7.20.5 Jazz Pharmaceuticals Key News
7.21 Sanofi
7.21.1 Sanofi Corporate Summary
7.21.2 Sanofi Business Overview
7.21.3 Sanofi Adrenoleukodystrophy Treatment Major Product Offerings
7.21.4 Sanofi Adrenoleukodystrophy Treatment Revenue in Global Market (2017-2022)
7.21.5 Sanofi Key News
8 CONCLUSION
9 APPENDIX
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
1.1 Adrenoleukodystrophy Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Adrenoleukodystrophy Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 GLOBAL ADRENOLEUKODYSTROPHY TREATMENT OVERALL MARKET SIZE
2.1 Global Adrenoleukodystrophy Treatment Market Size: 2021 VS 2028
2.2 Global Adrenoleukodystrophy Treatment Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 COMPANY LANDSCAPE
3.1 Top Adrenoleukodystrophy Treatment Players in Global Market
3.2 Top Global Adrenoleukodystrophy Treatment Companies Ranked by Revenue
3.3 Global Adrenoleukodystrophy Treatment Revenue by Companies
3.4 Top 3 and Top 5 Adrenoleukodystrophy Treatment Companies in Global Market, by Revenue in 2021
3.5 Global Companies Adrenoleukodystrophy Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Adrenoleukodystrophy Treatment Players in Global Market
3.6.1 List of Global Tier 1 Adrenoleukodystrophy Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 Adrenoleukodystrophy Treatment Companies
4 MARKET SIGHTS BY PRODUCT
4.1 Overview
4.1.1 by Type - Global Adrenoleukodystrophy Treatment Market Size Markets, 2021 & 2028
4.1.2 Oral Drugs
4.1.3 Parenteral Drugs
4.2 By Type - Global Adrenoleukodystrophy Treatment Revenue & Forecasts
4.2.1 By Type - Global Adrenoleukodystrophy Treatment Revenue, 2017-2022
4.2.2 By Type - Global Adrenoleukodystrophy Treatment Revenue, 2023-2028
4.2.3 By Type - Global Adrenoleukodystrophy Treatment Revenue Market Share, 2017-2028
5 SIGHTS BY APPLICATION
5.1 Overview
5.1.1 By Application - Global Adrenoleukodystrophy Treatment Market Size, 2021 & 2028
5.1.2 Hospital
5.1.3 Clinic
5.1.4 Home Care
5.2 By Application - Global Adrenoleukodystrophy Treatment Revenue & Forecasts
5.2.1 By Application - Global Adrenoleukodystrophy Treatment Revenue, 2017-2022
5.2.2 By Application - Global Adrenoleukodystrophy Treatment Revenue, 2023-2028
5.2.3 By Application - Global Adrenoleukodystrophy Treatment Revenue Market Share, 2017-2028
6 SIGHTS BY REGION
6.1 By Region - Global Adrenoleukodystrophy Treatment Market Size, 2021 & 2028
6.2 By Region - Global Adrenoleukodystrophy Treatment Revenue & Forecasts
6.2.1 By Region - Global Adrenoleukodystrophy Treatment Revenue, 2017-2022
6.2.2 By Region - Global Adrenoleukodystrophy Treatment Revenue, 2023-2028
6.2.3 By Region - Global Adrenoleukodystrophy Treatment Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Adrenoleukodystrophy Treatment Revenue, 2017-2028
6.3.2 US Adrenoleukodystrophy Treatment Market Size, 2017-2028
6.3.3 Canada Adrenoleukodystrophy Treatment Market Size, 2017-2028
6.3.4 Mexico Adrenoleukodystrophy Treatment Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Adrenoleukodystrophy Treatment Revenue, 2017-2028
6.4.2 Germany Adrenoleukodystrophy Treatment Market Size, 2017-2028
6.4.3 France Adrenoleukodystrophy Treatment Market Size, 2017-2028
6.4.4 U.K. Adrenoleukodystrophy Treatment Market Size, 2017-2028
6.4.5 Italy Adrenoleukodystrophy Treatment Market Size, 2017-2028
6.4.6 Russia Adrenoleukodystrophy Treatment Market Size, 2017-2028
6.4.7 Nordic Countries Adrenoleukodystrophy Treatment Market Size, 2017-2028
6.4.8 Benelux Adrenoleukodystrophy Treatment Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Adrenoleukodystrophy Treatment Revenue, 2017-2028
6.5.2 China Adrenoleukodystrophy Treatment Market Size, 2017-2028
6.5.3 Japan Adrenoleukodystrophy Treatment Market Size, 2017-2028
6.5.4 South Korea Adrenoleukodystrophy Treatment Market Size, 2017-2028
6.5.5 Southeast Asia Adrenoleukodystrophy Treatment Market Size, 2017-2028
6.5.6 India Adrenoleukodystrophy Treatment Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Adrenoleukodystrophy Treatment Revenue, 2017-2028
6.6.2 Brazil Adrenoleukodystrophy Treatment Market Size, 2017-2028
6.6.3 Argentina Adrenoleukodystrophy Treatment Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Adrenoleukodystrophy Treatment Revenue, 2017-2028
6.7.2 Turkey Adrenoleukodystrophy Treatment Market Size, 2017-2028
6.7.3 Israel Adrenoleukodystrophy Treatment Market Size, 2017-2028
6.7.4 Saudi Arabia Adrenoleukodystrophy Treatment Market Size, 2017-2028
6.7.5 UAE Adrenoleukodystrophy Treatment Market Size, 2017-2028
7 PLAYERS PROFILES
7.1 bluebird bio
7.1.1 bluebird bio Corporate Summary
7.1.2 bluebird bio Business Overview
7.1.3 bluebird bio Adrenoleukodystrophy Treatment Major Product Offerings
7.1.4 bluebird bio Adrenoleukodystrophy Treatment Revenue in Global Market (2017-2022)
7.1.5 bluebird bio Key News
7.2 Orpheris
7.2.1 Orpheris Corporate Summary
7.2.2 Orpheris Business Overview
7.2.3 Orpheris Adrenoleukodystrophy Treatment Major Product Offerings
7.2.4 Orpheris Adrenoleukodystrophy Treatment Revenue in Global Market (2017-2022)
7.2.5 Orpheris Key News
7.3 MedDay Pharmaceuticals
7.3.1 MedDay Pharmaceuticals Corporate Summary
7.3.2 MedDay Pharmaceuticals Business Overview
7.3.3 MedDay Pharmaceuticals Adrenoleukodystrophy Treatment Major Product Offerings
7.3.4 MedDay Pharmaceuticals Adrenoleukodystrophy Treatment Revenue in Global Market (2017-2022)
7.3.5 MedDay Pharmaceuticals Key News
7.4 MINORYX THERAPEUTICS SL
7.4.1 MINORYX THERAPEUTICS SL Corporate Summary
7.4.2 MINORYX THERAPEUTICS SL Business Overview
7.4.3 MINORYX THERAPEUTICS SL Adrenoleukodystrophy Treatment Major Product Offerings
7.4.4 MINORYX THERAPEUTICS SL Adrenoleukodystrophy Treatment Revenue in Global Market (2017-2022)
7.4.5 MINORYX THERAPEUTICS SL Key News
7.5 Pfizer
7.5.1 Pfizer Corporate Summary
7.5.2 Pfizer Business Overview
7.5.3 Pfizer Adrenoleukodystrophy Treatment Major Product Offerings
7.5.4 Pfizer Adrenoleukodystrophy Treatment Revenue in Global Market (2017-2022)
7.5.5 Pfizer Key News
7.6 Amgen
7.6.1 Amgen Corporate Summary
7.6.2 Amgen Business Overview
7.6.3 Amgen Adrenoleukodystrophy Treatment Major Product Offerings
7.6.4 Amgen Adrenoleukodystrophy Treatment Revenue in Global Market (2017-2022)
7.6.5 Amgen Key News
7.7 AstraZeneca
7.7.1 AstraZeneca Corporate Summary
7.7.2 AstraZeneca Business Overview
7.7.3 AstraZeneca Adrenoleukodystrophy Treatment Major Product Offerings
7.7.4 AstraZeneca Adrenoleukodystrophy Treatment Revenue in Global Market (2017-2022)
7.7.5 AstraZeneca Key News
7.8 Abbott
7.8.1 Abbott Corporate Summary
7.8.2 Abbott Business Overview
7.8.3 Abbott Adrenoleukodystrophy Treatment Major Product Offerings
7.8.4 Abbott Adrenoleukodystrophy Treatment Revenue in Global Market (2017-2022)
7.8.5 Abbott Key News
7.9 agtc
7.9.1 agtc Corporate Summary
7.9.2 agtc Business Overview
7.9.3 agtc Adrenoleukodystrophy Treatment Major Product Offerings
7.9.4 agtc Adrenoleukodystrophy Treatment Revenue in Global Market (2017-2022)
7.9.5 agtc Key News
7.10 ReceptoPharm
7.10.1 ReceptoPharm Corporate Summary
7.10.2 ReceptoPharm Business Overview
7.10.3 ReceptoPharm Adrenoleukodystrophy Treatment Major Product Offerings
7.10.4 ReceptoPharm Adrenoleukodystrophy Treatment Revenue in Global Market (2017-2022)
7.10.5 ReceptoPharm Key News
7.11 The Myelin Project
7.11.1 The Myelin Project Corporate Summary
7.11.2 The Myelin Project Business Overview
7.11.3 The Myelin Project Adrenoleukodystrophy Treatment Major Product Offerings
7.11.4 The Myelin Project Adrenoleukodystrophy Treatment Revenue in Global Market (2017-2022)
7.11.5 The Myelin Project Key News
7.12 SOM Biotech
7.12.1 SOM Biotech Corporate Summary
7.12.2 SOM Biotech Business Overview
7.12.3 SOM Biotech Adrenoleukodystrophy Treatment Major Product Offerings
7.12.4 SOM Biotech Adrenoleukodystrophy Treatment Revenue in Global Market (2017-2022)
7.12.5 SOM Biotech Key News
7.13 Viking Therapeutics
7.13.1 Viking Therapeutics Corporate Summary
7.13.2 Viking Therapeutics Business Overview
7.13.3 Viking Therapeutics Adrenoleukodystrophy Treatment Major Product Offerings
7.13.4 Viking Therapeutics Adrenoleukodystrophy Treatment Revenue in Global Market (2017-2022)
7.13.5 Viking Therapeutics Key News
7.14 Nutra Pharma Corporation
7.14.1 Nutra Pharma Corporation Corporate Summary
7.14.2 Nutra Pharma Corporation Business Overview
7.14.3 Nutra Pharma Corporation Adrenoleukodystrophy Treatment Major Product Offerings
7.14.4 Nutra Pharma Corporation Adrenoleukodystrophy Treatment Revenue in Global Market (2017-2022)
7.14.5 Nutra Pharma Corporation Key News
7.15 Genetix Biotech
7.15.1 Genetix Biotech Corporate Summary
7.15.2 Genetix Biotech Business Overview
7.15.3 Genetix Biotech Adrenoleukodystrophy Treatment Major Product Offerings
7.15.4 Genetix Biotech Adrenoleukodystrophy Treatment Revenue in Global Market (2017-2022)
7.15.5 Genetix Biotech Key News
7.16 Magenta Therapeutics
7.16.1 Magenta Therapeutics Corporate Summary
7.16.2 Magenta Therapeutics Business Overview
7.16.3 Magenta Therapeutics Adrenoleukodystrophy Treatment Major Product Offerings
7.16.4 Magenta Therapeutics Adrenoleukodystrophy Treatment Revenue in Global Market (2017-2022)
7.16.5 Magenta Therapeutics Key News
7.17 NeuroVia
7.17.1 NeuroVia Corporate Summary
7.17.2 NeuroVia Business Overview
7.17.3 NeuroVia Adrenoleukodystrophy Treatment Major Product Offerings
7.17.4 NeuroVia Adrenoleukodystrophy Treatment Revenue in Global Market (2017-2022)
7.17.5 NeuroVia Key News
7.18 Novartis
7.18.1 Novartis Corporate Summary
7.18.2 Novartis Business Overview
7.18.3 Novartis Adrenoleukodystrophy Treatment Major Product Offerings
7.18.4 Novartis Adrenoleukodystrophy Treatment Revenue in Global Market (2017-2022)
7.18.5 Novartis Key News
7.19 CELGENE CORPORATION
7.19.1 CELGENE CORPORATION Corporate Summary
7.19.2 CELGENE CORPORATION Business Overview
7.19.3 CELGENE CORPORATION Adrenoleukodystrophy Treatment Major Product Offerings
7.19.4 CELGENE CORPORATION Adrenoleukodystrophy Treatment Revenue in Global Market (2017-2022)
7.19.5 CELGENE CORPORATION Key News
7.20 Jazz Pharmaceuticals
7.20.1 Jazz Pharmaceuticals Corporate Summary
7.20.2 Jazz Pharmaceuticals Business Overview
7.20.3 Jazz Pharmaceuticals Adrenoleukodystrophy Treatment Major Product Offerings
7.20.4 Jazz Pharmaceuticals Adrenoleukodystrophy Treatment Revenue in Global Market (2017-2022)
7.20.5 Jazz Pharmaceuticals Key News
7.21 Sanofi
7.21.1 Sanofi Corporate Summary
7.21.2 Sanofi Business Overview
7.21.3 Sanofi Adrenoleukodystrophy Treatment Major Product Offerings
7.21.4 Sanofi Adrenoleukodystrophy Treatment Revenue in Global Market (2017-2022)
7.21.5 Sanofi Key News
8 CONCLUSION
9 APPENDIX
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES
Table 1. Adrenoleukodystrophy Treatment Market Opportunities & Trends in Global Market
Table 2. Adrenoleukodystrophy Treatment Market Drivers in Global Market
Table 3. Adrenoleukodystrophy Treatment Market Restraints in Global Market
Table 4. Key Players of Adrenoleukodystrophy Treatment in Global Market
Table 5. Top Adrenoleukodystrophy Treatment Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Adrenoleukodystrophy Treatment Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Adrenoleukodystrophy Treatment Revenue Share by Companies, 2017-2022
Table 8. Global Companies Adrenoleukodystrophy Treatment Product Type
Table 9. List of Global Tier 1 Adrenoleukodystrophy Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Adrenoleukodystrophy Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Adrenoleukodystrophy Treatment Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Adrenoleukodystrophy Treatment Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Adrenoleukodystrophy Treatment Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Adrenoleukodystrophy Treatment Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Adrenoleukodystrophy Treatment Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Adrenoleukodystrophy Treatment Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2023-2028
Table 30. bluebird bio Corporate Summary
Table 31. bluebird bio Adrenoleukodystrophy Treatment Product Offerings
Table 32. bluebird bio Adrenoleukodystrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 33. Orpheris Corporate Summary
Table 34. Orpheris Adrenoleukodystrophy Treatment Product Offerings
Table 35. Orpheris Adrenoleukodystrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 36. MedDay Pharmaceuticals Corporate Summary
Table 37. MedDay Pharmaceuticals Adrenoleukodystrophy Treatment Product Offerings
Table 38. MedDay Pharmaceuticals Adrenoleukodystrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 39. MINORYX THERAPEUTICS SL Corporate Summary
Table 40. MINORYX THERAPEUTICS SL Adrenoleukodystrophy Treatment Product Offerings
Table 41. MINORYX THERAPEUTICS SL Adrenoleukodystrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 42. Pfizer Corporate Summary
Table 43. Pfizer Adrenoleukodystrophy Treatment Product Offerings
Table 44. Pfizer Adrenoleukodystrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 45. Amgen Corporate Summary
Table 46. Amgen Adrenoleukodystrophy Treatment Product Offerings
Table 47. Amgen Adrenoleukodystrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 48. AstraZeneca Corporate Summary
Table 49. AstraZeneca Adrenoleukodystrophy Treatment Product Offerings
Table 50. AstraZeneca Adrenoleukodystrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 51. Abbott Corporate Summary
Table 52. Abbott Adrenoleukodystrophy Treatment Product Offerings
Table 53. Abbott Adrenoleukodystrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 54. agtc Corporate Summary
Table 55. agtc Adrenoleukodystrophy Treatment Product Offerings
Table 56. agtc Adrenoleukodystrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 57. ReceptoPharm Corporate Summary
Table 58. ReceptoPharm Adrenoleukodystrophy Treatment Product Offerings
Table 59. ReceptoPharm Adrenoleukodystrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 60. The Myelin Project Corporate Summary
Table 61. The Myelin Project Adrenoleukodystrophy Treatment Product Offerings
Table 62. The Myelin Project Adrenoleukodystrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 63. SOM Biotech Corporate Summary
Table 64. SOM Biotech Adrenoleukodystrophy Treatment Product Offerings
Table 65. SOM Biotech Adrenoleukodystrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 66. Viking Therapeutics Corporate Summary
Table 67. Viking Therapeutics Adrenoleukodystrophy Treatment Product Offerings
Table 68. Viking Therapeutics Adrenoleukodystrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 69. Nutra Pharma Corporation Corporate Summary
Table 70. Nutra Pharma Corporation Adrenoleukodystrophy Treatment Product Offerings
Table 71. Nutra Pharma Corporation Adrenoleukodystrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 72. Genetix Biotech Corporate Summary
Table 73. Genetix Biotech Adrenoleukodystrophy Treatment Product Offerings
Table 74. Genetix Biotech Adrenoleukodystrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 75. Magenta Therapeutics Corporate Summary
Table 76. Magenta Therapeutics Adrenoleukodystrophy Treatment Product Offerings
Table 77. Magenta Therapeutics Adrenoleukodystrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 78. NeuroVia Corporate Summary
Table 79. NeuroVia Adrenoleukodystrophy Treatment Product Offerings
Table 80. NeuroVia Adrenoleukodystrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 81. Novartis Corporate Summary
Table 82. Novartis Adrenoleukodystrophy Treatment Product Offerings
Table 83. Novartis Adrenoleukodystrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 84. CELGENE CORPORATION Corporate Summary
Table 85. CELGENE CORPORATION Adrenoleukodystrophy Treatment Product Offerings
Table 86. CELGENE CORPORATION Adrenoleukodystrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 87. Jazz Pharmaceuticals Corporate Summary
Table 88. Jazz Pharmaceuticals Adrenoleukodystrophy Treatment Product Offerings
Table 89. Jazz Pharmaceuticals Adrenoleukodystrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 90. Sanofi Corporate Summary
Table 91. Sanofi Adrenoleukodystrophy Treatment Product Offerings
Table 92. Sanofi Adrenoleukodystrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 1. Adrenoleukodystrophy Treatment Market Opportunities & Trends in Global Market
Table 2. Adrenoleukodystrophy Treatment Market Drivers in Global Market
Table 3. Adrenoleukodystrophy Treatment Market Restraints in Global Market
Table 4. Key Players of Adrenoleukodystrophy Treatment in Global Market
Table 5. Top Adrenoleukodystrophy Treatment Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Adrenoleukodystrophy Treatment Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Adrenoleukodystrophy Treatment Revenue Share by Companies, 2017-2022
Table 8. Global Companies Adrenoleukodystrophy Treatment Product Type
Table 9. List of Global Tier 1 Adrenoleukodystrophy Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Adrenoleukodystrophy Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Adrenoleukodystrophy Treatment Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Adrenoleukodystrophy Treatment Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Adrenoleukodystrophy Treatment Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Adrenoleukodystrophy Treatment Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Adrenoleukodystrophy Treatment Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Adrenoleukodystrophy Treatment Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2023-2028
Table 30. bluebird bio Corporate Summary
Table 31. bluebird bio Adrenoleukodystrophy Treatment Product Offerings
Table 32. bluebird bio Adrenoleukodystrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 33. Orpheris Corporate Summary
Table 34. Orpheris Adrenoleukodystrophy Treatment Product Offerings
Table 35. Orpheris Adrenoleukodystrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 36. MedDay Pharmaceuticals Corporate Summary
Table 37. MedDay Pharmaceuticals Adrenoleukodystrophy Treatment Product Offerings
Table 38. MedDay Pharmaceuticals Adrenoleukodystrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 39. MINORYX THERAPEUTICS SL Corporate Summary
Table 40. MINORYX THERAPEUTICS SL Adrenoleukodystrophy Treatment Product Offerings
Table 41. MINORYX THERAPEUTICS SL Adrenoleukodystrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 42. Pfizer Corporate Summary
Table 43. Pfizer Adrenoleukodystrophy Treatment Product Offerings
Table 44. Pfizer Adrenoleukodystrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 45. Amgen Corporate Summary
Table 46. Amgen Adrenoleukodystrophy Treatment Product Offerings
Table 47. Amgen Adrenoleukodystrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 48. AstraZeneca Corporate Summary
Table 49. AstraZeneca Adrenoleukodystrophy Treatment Product Offerings
Table 50. AstraZeneca Adrenoleukodystrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 51. Abbott Corporate Summary
Table 52. Abbott Adrenoleukodystrophy Treatment Product Offerings
Table 53. Abbott Adrenoleukodystrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 54. agtc Corporate Summary
Table 55. agtc Adrenoleukodystrophy Treatment Product Offerings
Table 56. agtc Adrenoleukodystrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 57. ReceptoPharm Corporate Summary
Table 58. ReceptoPharm Adrenoleukodystrophy Treatment Product Offerings
Table 59. ReceptoPharm Adrenoleukodystrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 60. The Myelin Project Corporate Summary
Table 61. The Myelin Project Adrenoleukodystrophy Treatment Product Offerings
Table 62. The Myelin Project Adrenoleukodystrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 63. SOM Biotech Corporate Summary
Table 64. SOM Biotech Adrenoleukodystrophy Treatment Product Offerings
Table 65. SOM Biotech Adrenoleukodystrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 66. Viking Therapeutics Corporate Summary
Table 67. Viking Therapeutics Adrenoleukodystrophy Treatment Product Offerings
Table 68. Viking Therapeutics Adrenoleukodystrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 69. Nutra Pharma Corporation Corporate Summary
Table 70. Nutra Pharma Corporation Adrenoleukodystrophy Treatment Product Offerings
Table 71. Nutra Pharma Corporation Adrenoleukodystrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 72. Genetix Biotech Corporate Summary
Table 73. Genetix Biotech Adrenoleukodystrophy Treatment Product Offerings
Table 74. Genetix Biotech Adrenoleukodystrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 75. Magenta Therapeutics Corporate Summary
Table 76. Magenta Therapeutics Adrenoleukodystrophy Treatment Product Offerings
Table 77. Magenta Therapeutics Adrenoleukodystrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 78. NeuroVia Corporate Summary
Table 79. NeuroVia Adrenoleukodystrophy Treatment Product Offerings
Table 80. NeuroVia Adrenoleukodystrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 81. Novartis Corporate Summary
Table 82. Novartis Adrenoleukodystrophy Treatment Product Offerings
Table 83. Novartis Adrenoleukodystrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 84. CELGENE CORPORATION Corporate Summary
Table 85. CELGENE CORPORATION Adrenoleukodystrophy Treatment Product Offerings
Table 86. CELGENE CORPORATION Adrenoleukodystrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 87. Jazz Pharmaceuticals Corporate Summary
Table 88. Jazz Pharmaceuticals Adrenoleukodystrophy Treatment Product Offerings
Table 89. Jazz Pharmaceuticals Adrenoleukodystrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 90. Sanofi Corporate Summary
Table 91. Sanofi Adrenoleukodystrophy Treatment Product Offerings
Table 92. Sanofi Adrenoleukodystrophy Treatment Revenue (US$, Mn), (2017-2022)
LIST OF FIGURES
Figure 1. Adrenoleukodystrophy Treatment Segment by Type in 2021
Figure 2. Adrenoleukodystrophy Treatment Segment by Application in 2021
Figure 3. Global Adrenoleukodystrophy Treatment Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Adrenoleukodystrophy Treatment Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Adrenoleukodystrophy Treatment Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Adrenoleukodystrophy Treatment Revenue in 2021
Figure 8. By Type - Global Adrenoleukodystrophy Treatment Revenue Market Share, 2017-2028
Figure 9. By Application - Global Adrenoleukodystrophy Treatment Revenue Market Share, 2017-2028
Figure 10. By Region - Global Adrenoleukodystrophy Treatment Revenue Market Share, 2017-2028
Figure 11. By Country - North America Adrenoleukodystrophy Treatment Revenue Market Share, 2017-2028
Figure 12. US Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Adrenoleukodystrophy Treatment Revenue Market Share, 2017-2028
Figure 16. Germany Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 17. France Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Adrenoleukodystrophy Treatment Revenue Market Share, 2017-2028
Figure 24. China Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 28. India Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Adrenoleukodystrophy Treatment Revenue Market Share, 2017-2028
Figure 30. Brazil Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Adrenoleukodystrophy Treatment Revenue Market Share, 2017-2028
Figure 33. Turkey Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 37. bluebird bio Adrenoleukodystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Orpheris Adrenoleukodystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. MedDay Pharmaceuticals Adrenoleukodystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. MINORYX THERAPEUTICS SL Adrenoleukodystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Pfizer Adrenoleukodystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Amgen Adrenoleukodystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. AstraZeneca Adrenoleukodystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Abbott Adrenoleukodystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. agtc Adrenoleukodystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. ReceptoPharm Adrenoleukodystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. The Myelin Project Adrenoleukodystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. SOM Biotech Adrenoleukodystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Viking Therapeutics Adrenoleukodystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 50. Nutra Pharma Corporation Adrenoleukodystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 51. Genetix Biotech Adrenoleukodystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 52. Magenta Therapeutics Adrenoleukodystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 53. NeuroVia Adrenoleukodystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 54. Novartis Adrenoleukodystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 55. CELGENE CORPORATION Adrenoleukodystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 56. Jazz Pharmaceuticals Adrenoleukodystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 57. Sanofi Adrenoleukodystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 1. Adrenoleukodystrophy Treatment Segment by Type in 2021
Figure 2. Adrenoleukodystrophy Treatment Segment by Application in 2021
Figure 3. Global Adrenoleukodystrophy Treatment Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Adrenoleukodystrophy Treatment Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Adrenoleukodystrophy Treatment Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Adrenoleukodystrophy Treatment Revenue in 2021
Figure 8. By Type - Global Adrenoleukodystrophy Treatment Revenue Market Share, 2017-2028
Figure 9. By Application - Global Adrenoleukodystrophy Treatment Revenue Market Share, 2017-2028
Figure 10. By Region - Global Adrenoleukodystrophy Treatment Revenue Market Share, 2017-2028
Figure 11. By Country - North America Adrenoleukodystrophy Treatment Revenue Market Share, 2017-2028
Figure 12. US Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Adrenoleukodystrophy Treatment Revenue Market Share, 2017-2028
Figure 16. Germany Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 17. France Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Adrenoleukodystrophy Treatment Revenue Market Share, 2017-2028
Figure 24. China Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 28. India Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Adrenoleukodystrophy Treatment Revenue Market Share, 2017-2028
Figure 30. Brazil Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Adrenoleukodystrophy Treatment Revenue Market Share, 2017-2028
Figure 33. Turkey Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Adrenoleukodystrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 37. bluebird bio Adrenoleukodystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Orpheris Adrenoleukodystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. MedDay Pharmaceuticals Adrenoleukodystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. MINORYX THERAPEUTICS SL Adrenoleukodystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Pfizer Adrenoleukodystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Amgen Adrenoleukodystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. AstraZeneca Adrenoleukodystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Abbott Adrenoleukodystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. agtc Adrenoleukodystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. ReceptoPharm Adrenoleukodystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. The Myelin Project Adrenoleukodystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. SOM Biotech Adrenoleukodystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Viking Therapeutics Adrenoleukodystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 50. Nutra Pharma Corporation Adrenoleukodystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 51. Genetix Biotech Adrenoleukodystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 52. Magenta Therapeutics Adrenoleukodystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 53. NeuroVia Adrenoleukodystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 54. Novartis Adrenoleukodystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 55. CELGENE CORPORATION Adrenoleukodystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 56. Jazz Pharmaceuticals Adrenoleukodystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 57. Sanofi Adrenoleukodystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
